decapeptyl depot 3.75 mg (Triptorelin) is a gonadotropin-releasing hormone agonist (GnRH agonist). By causing constant stimulation of the pituitary, decapeptyl depot 3.75 mg decreases pituitary secretion of gonadotropins luteinizing hormone (LH) and follicle stimulating hormone (FSH).
Decapeptyl Depot is indicated in the man in advanced prostate cancer-the treatment of attack, before using the extended release form. The effect of Decapeptyl Depot is much more favorable in patients who received other hormonal treatment. Women while in treatment of female infertility.
Prostate Cancer: Most prostate cancers need a supply of the hormone testosterone to grow.Triptorelin reduces the production of luteinising hormone, which leads to a reduction in testosterone levels. This may shrink or slow down the development of the cancer.
The man taking a daily dose of Decapeptyl Depot (Triptorelin) can increase blood levels of initial LH and FSH that causes increased blood levels of testosterone page. Continued therapy reduces the levels of LH, FSH levels that decrease testosterone administration throughout the product. In parallel we can see an increase in initial onset transient acid phosphatase treatment. During treatment there is a noticeable improvement in functional and objective data. Early treatment can be seen increased clinical symptoms (especially bone pain), but these events are rare and generally transient. They cause surveillance in the first two weeks of treatment, especially in patients at risk of obstruction of the excretory or spinal nerve compression (vertebral metastases).
Decapeptyl Depot is available in 0.1mg and 3.75mg strength versions. When given to prevent premature luteinizing hormone surges in female patients, the dosage is 0.1mg per day.